Symptoms and General Pathology

All Conditions

Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Recurrence

Head and Neck Neoplasms

Laryngeal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Gemcitabine

Carboplatin

Pemetrexed

Antimetabolites

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Folinic Acid

Folate

Vitamin B9

4 doses of induction chemotherapy every 2weeks, IV (in the vein)

Induction Chemotherapy:

4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.

Chemoradiotherapy:

Day 1,22, and 43through IV infusion over a period of 10 minutes

Chemoradiotherapy:

Day 1, 22 and 4 through IV infusion over a period of 1 hour.

Ezra Cohen, MD

The purpose of this study is to determine 1-year survival of previously irradiated Head and Neck cancer (HNC) patients with loco-regional recurrent disease treated with induction chemotherapy with pemetrexed and gemcitabine followed concomitant pemetrexed, carboplatin and daily radiotherapy.

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

University of Chicago

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients	NCT01172470	Head and Neck C...	Gemcitabine Pemetrexed Carboplatin	18 Years -	University of Chicago
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients	NCT01172470	Head and Neck C...	Gemcitabine Pemetrexed Carboplatin	18 Years -	University of Chicago

Spots Global Cancer Trial Database for larynx, lip, oral cavity and pharynx